Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
AVAILABLE
NCT02632994
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Sponsor: Eli Lilly and Company
View on ClinicalTrials.gov
Summary
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-06-25
Healthy Volunteers
Not specified
Conditions
Interventions
DRUG
LY2503029
Administered orally.
DRUG
LY3023414
Administered orally.
DRUG
LY3838915
Administered orally.
DRUG
LY3847429
Administered orally.
Locations (3)
UCLA Medical Center
Torrance, California, United States
Fort Wayne Oncology & Hematology
Fort Wayne, Indiana, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States